| 蒋屏东,孙 慧,郑 渊,胡 佳,赖美玲,张瑞丽.重组人表皮生长因子在面部瘢痕修复治疗中的应用[J].现代生物医学进展英文版,2017,17(33):6502-6505. |
| 重组人表皮生长因子在面部瘢痕修复治疗中的应用 |
| Application of Recombinant Human Epidermal Growth Factor for the Repair of Facial Scar |
| Received:June 10, 2017 Revised:June 30, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.33.023 |
| 中文关键词: 面部瘢痕 重组人表皮生长因子 修复 创面 |
| 英文关键词: Facial scar Recombinant human epidermal growth factor Repair Wound |
| 基金项目:江苏省自然科学基金项目(BK20150121) |
|
| Hits: 156 |
| Download times: 141 |
| 中文摘要: |
| 摘要 目的：分析重组人表皮生长因子(rhEGF)在面部瘢痕修复治疗中的应用价值。方法：选择2013年3月-2016年2月我院收治的80例面部瘢痕患者作为研究对象，按随机数字表法分为对照组与观察组各40例，两组均应用二氧化碳点阵激光进行面部瘢痕修复治疗，观察组术后加用rhEGF敷于皮肤表面，对照组则采用等渗盐水敷于皮肤表面，比较两组治疗不同时间创面愈合率、创面愈合时间及换药时疼痛情况，测定创面愈合后患者瘢痕面积，并评定创面处理后不同时间患者肉芽组织成熟情况、创面愈合后瘢痕面积及不良反应的发生情况。结果：两组术后7 d、术后14 d创面愈合率均显著高于术后3 d(P<0.05)，观察组术后不同时间创面愈合率均显著高于对照组(P<0.05)；观察组创面愈合时间短于对照组，其创面愈合后瘢痕面积小于对照组(P<0.05)；观察组换药时疼痛程度低于对照组，其轻度疼痛所占比例高于对照组(P<0.05)；观察组术后7 d、14 d肉芽组织成熟分级均高于对照组(P<0.05)。两组均未见炎症全身不良反应。结论：reEGF可促进面部瘢痕患者创面修复，缩短创面愈合时间，缩小瘢痕面积，减轻患者换药疼痛程度，促进肉芽组织成熟，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the application value of recombinant human epidermal growth factor (rhEGF) for the repair of facial scar. Methods: 80 cases of patients with facial scar treated in our hospital from March 2013 to February 2016 were selected as the study subjects and divided into the control group and the observation group by the random number table method, with 40 cases in each group. Both groups were treated with carbon dioxide fractional laser for facial scar repair. The observation group was additionally treated by external application of rhEGF on skin surface after surgery, while the control group was treated by external application of isotonic saline on skin surface. The wound healing rate, wound healing time and pain during dressing change were compared between the two groups at different time points. The scar area after wound healing was measured, and the maturity of granulation tissues at different time points after treating wounds, the scar area after wound healing and the occurrence of adverse reactions were compared between two groups. Results: The wound healing rates in the two groups on the 7th and 14th day after surgery were significantly higher than that on the 3rd day after surgery (P<0.05), and the healing rates in the observation group were significantly higher than those in the control group at the same time point (P<0.05). The wound healing time of the observation group was shorter than that of the control group, and the scar area after wound healing was smaller than that of the control group (P<0.05). The pain degree of observation group was lower than that in the control group, and the proportion of mild pain was higher than that in the control group (P<0.05). The grades of mature granulation tissues in the observation group on the 7th and 14th day after surgery were higher than those in the control group (P<0.05). There was no inflammation or systemic adverse reactions in the two groups. Conclusion: ReEGF can promote the wound healing of patients with facial scars, shorten the wound healing time, reduce the scar area, relieve the pain degree during dressing change, and promote granulation tis- sue maturation with high safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
